NR3C2 and heart failure: For over decades, angiotensin-converting enzyme inhibitors (ACEi) [106], angiotensin receptor blocker (ARB) [107], and mineralocorticoid receptor antagonist (MRA) [108] have been used as heart failure treatment by targeting the RAAS as anti-remodeling drugs [106–108].